Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | VNN1 | O95497 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1202887 | 0.89 | FYN (0.52) | MEN1KMT2AVNN1PIM1FYN | |
| SCHEMBL1202799 | 0.87 | PIM1 (0.56) | SMN1; SMN2PIM1FYNKDM4ENTRK1 | |
| SCHEMBL1203493 | 0.86 | KDM4E (0.61) | PIM1FYNKDM4ENTRK1 | |
| SCHEMBL1202730 | 0.83 | NTRK1 (0.55) | SMN1; SMN2MEN1KMT2AVNN1PIM1 | |
| SCHEMBL1202320 | 0.81 | PIM1 (0.66) | PIM1FYNKDM4ENTRK1 | |
| SCHEMBL1202385 | 0.78 | FYN (0.47) | PIM1FYNKDM4ENPC1RAB9A | |
| SCHEMBL1203552 | 0.78 | FYN (0.57) | PIM1FYNKDM4ENTRK1 | |
| SCHEMBL1203279 | 0.78 | IKBKB (0.62) | FYN | |
| SCHEMBL1202940 | 0.77 | FYN (0.56) | KMT2AVNN1PIM1FYNNPC1 | |
| SCHEMBL1203488 | 0.76 | FYN (0.52) | MEN1KMT2APIM1FYNNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-02-24 | — | — | US | disclosed |
| EP-2217601-A1 | IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009060197-A1 | IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | PIM1, PIM3, PIM2 | SMN1; SMN2 4097/4885MEN1 2279/4885KMT2A 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.